BACKGROUND The prognosis for oesophageal carcinoma is poor,but once distant metastases emerge the prognosis is considered hopeless.There is no consistent protocol for the early identification and aggressive management...BACKGROUND The prognosis for oesophageal carcinoma is poor,but once distant metastases emerge the prognosis is considered hopeless.There is no consistent protocol for the early identification and aggressive management of metastases.AIM To examine the outcome of a policy of active postoperative surveillance with aggressive treatment of confirmed metastases.METHODS A prospectively maintained database of 205 patients diagnosed with oesophageal carcinoma between 1998 and 2019 and treated with curative intent was interrogated for patients with metastases,either at diagnosis or on follow-up surveillance and treated for cure.This cohort was compared with incomplete clinical responders to neoadjuvant chemoradiotherapy(nCRT)who subsequently underwent surgery on their primary tumour.Overall survival was estimated using the Kaplan-Meier method,and the log-rank test was used to compare survival differences between groups.RESULTS Of 205 patients,11(5.4%)had metastases treated for cure(82%male;median age 60 years;9 adenocarcinoma and 2 squamous cell carcinomas).All had undergone neoadjuvant chemotherapy or chemoradiotherapy,followed by surgery in all but 1 case.Of the 11 patients,4 had metastatic disease at diagnosis,of whom 3 were successfully downstaged with nCRT before definitive surgery;2 of these 4 also developed oligometastatic recurrence and were treated with curative intent.Following definitive treatment,7 had treatment for metachronous oligometastatic disease;5 of whom underwent metastasectomy(adrenal×2;lung×2;liver×1).The median overall survival was 10.9 years[95%confidence interval(CI):0.7-21.0 years],which was statistically significantly longer than incomplete clinical responders undergoing surgery on the primary tumour without metastatic intervention[n=62;median overall survival=1.9(95%CI:1.1-2.7;P=0.012].The cumulative proportion surviving 1,3,and 5 years was 100%,91%,and 61%,respectively compared to 71%,36%,and 25%for incomplete clinical responders undergoing surgery on the primary tumour who did not undergo treatment for metastatic disease.CONCLUSION Metastatic oesophageal cancer represents a unique challenge,but aggressive treatment can be rewarded with impressive survival data.In view of recent advances in targeted therapies,intensive follow-up may yield a greater number of patients with curative potential and thus improved long-term survival.展开更多
文摘BACKGROUND The prognosis for oesophageal carcinoma is poor,but once distant metastases emerge the prognosis is considered hopeless.There is no consistent protocol for the early identification and aggressive management of metastases.AIM To examine the outcome of a policy of active postoperative surveillance with aggressive treatment of confirmed metastases.METHODS A prospectively maintained database of 205 patients diagnosed with oesophageal carcinoma between 1998 and 2019 and treated with curative intent was interrogated for patients with metastases,either at diagnosis or on follow-up surveillance and treated for cure.This cohort was compared with incomplete clinical responders to neoadjuvant chemoradiotherapy(nCRT)who subsequently underwent surgery on their primary tumour.Overall survival was estimated using the Kaplan-Meier method,and the log-rank test was used to compare survival differences between groups.RESULTS Of 205 patients,11(5.4%)had metastases treated for cure(82%male;median age 60 years;9 adenocarcinoma and 2 squamous cell carcinomas).All had undergone neoadjuvant chemotherapy or chemoradiotherapy,followed by surgery in all but 1 case.Of the 11 patients,4 had metastatic disease at diagnosis,of whom 3 were successfully downstaged with nCRT before definitive surgery;2 of these 4 also developed oligometastatic recurrence and were treated with curative intent.Following definitive treatment,7 had treatment for metachronous oligometastatic disease;5 of whom underwent metastasectomy(adrenal×2;lung×2;liver×1).The median overall survival was 10.9 years[95%confidence interval(CI):0.7-21.0 years],which was statistically significantly longer than incomplete clinical responders undergoing surgery on the primary tumour without metastatic intervention[n=62;median overall survival=1.9(95%CI:1.1-2.7;P=0.012].The cumulative proportion surviving 1,3,and 5 years was 100%,91%,and 61%,respectively compared to 71%,36%,and 25%for incomplete clinical responders undergoing surgery on the primary tumour who did not undergo treatment for metastatic disease.CONCLUSION Metastatic oesophageal cancer represents a unique challenge,but aggressive treatment can be rewarded with impressive survival data.In view of recent advances in targeted therapies,intensive follow-up may yield a greater number of patients with curative potential and thus improved long-term survival.
